CCL2 and endothelial dysfunction: Novel risk factors, such as serum calcitonin [24], low-grade inflammation [25], multifunctional molecules (e.g. TWEAK and MCP-1) [26,27], and endothelial dysfunction [28], were reported to be highly associated with advanced CAD in patients with kidney disease.